Abstract: The present invention provides a method for treating or reducing chronic inflammatory pain in a subject by administering to the subject a dose of an anti-IL-36R antibody.

Abstract: A nozzle assembly may be used to apply fluid to an advancing substrate. The nozzle assembly includes a nozzle body made from a first material. The nozzle body may include one or more abrasion resistant materials fused to the nozzle body. The nozzle body may be configured to deposit a fluid, using a shim plate, onto the advancing substrate. As the substrate advances past the nozzle assembly, the substrate and/or the fluid may contact the nozzle assembly resulting in wear. The one or more abrasion resistant materials, which is different than the first material of the nozzle body, may be fused to a portion of the nozzle body to reduce the wear and prolong the life of the nozzle body. Thus, the portion of the nozzle body having the abrasion resistant material is restored rather than having to replace the entire nozzle body.

Abstract: A nozzle assembly may be used to apply fluid to an advancing substrate. The nozzle assembly includes a nozzle body made from a first material. The nozzle body may include one or more abrasion resistant materials fused to the nozzle body. The nozzle body may be configured to deposit a fluid, using a shim plate, onto the advancing substrate. As the substrate advances past the nozzle assembly, the substrate and/or the fluid may contact the nozzle assembly resulting in wear. The one or more abrasion resistant materials, which is different than the first material of the nozzle body, may be fused to a portion of the nozzle body to reduce the wear and prolong the life of the nozzle body. Thus, the portion of the nozzle body having the abrasion resistant material is restored rather than having to replace the entire nozzle body.

Abstract: The invention provides a modified therapeutic agent, said modified agent comprising three or more membrane binding elements with low membrane affinity covalently associated with the agent which elements are capable of interacting independently and with thermodynamic additivity, with components of cellular or artificial membranes exposed to extracellular fluids wherein at least two membrane binding elements are lipophilic elements, which may be aliphatic acyl groups, which may be selected from the list consisting of Myristoyl, Decanoyl or Hexanoyl.

Abstract: The invention relates to a method for the transfer of molecular substances, for example proteins or nucleic acids in cells, in the case of using DNA combined with a possible gene expression. A prokaryotic nucleic acid-binding protein is used for the transfer, which is preferably obtained from a thermostable organism. Where the substance to be transferred is a nucleic acid, the protein forms a reversible complex with the nucleic acid. The prokaryotic protein condenses and compacts the nucleic acids. Said nucleic acids can be taken up in the target cells after suitable incubation.

Abstract: The invention provides a modified therapeutic agent, said modified agent comprising three or more membrane binding elements with low membrane affinity covalently associated with the agent which elements are capable of interacting independently and with thermodynamic additivity, with components of cellular or artificial membranes exposed to extracellular fluids wherein at least two membrane binding elements are lipophilic elements, which may be aliphatic acyl groups, which may be selected from the list consisting of Myristoyl, Decanoyl or Hexanoyl.

Abstract: The invention relates to a method for the transfer of molecular substances, for example proteins or nucleic acids in cells, in the case of using DNA combined with a possible gene expression. A prokaryotic nucleic acid-binding protein is used for the transfer, which is preferably obtained from a thermostable organism. Where the substance to be transferred is a nucleic acid, the protein forms a reversible complex with the nucleic acid. The prokaryotic protein condenses and compacts the nucleic acids. Said nucleic acids can be taken up in the target cells after suitable incubation.

Abstract: The invention relates to a method for the transfer of molecular substances, for example proteins or nucleic acids in cells, in the case of using DNA combined with a possible gene expression. A prokaryotic nucleic acid-binding protein is used for the transfer, which is preferably obtained from a thermostable organism. Where the substance to be transferred is a nucleic acid, the protein forms a reversible complex with the nucleic acid. The prokaryotic protein condenses and compacts the nucleic acids. Said nucleic acids can be taken up in the target cells after suitable incubation.

Abstract: The invention provides a modified therapeutic agent, said modified agent comprising three or more membrane binding elements with low membrane affinity covalently associated with the agent which elements are capable of interacting independently and with thermodynamic additivity, with components of cellular or artificial membranes exposed to extracellular fluids wherein at least two membrane binding elements are lipophilic elements, which may be aliphatic acyl groups, which may be selected from the list consisting of Myristoyl, Decanoyl or Hexanoyl.

Abstract: The invention relates to a method for packaging molecular substances in protein shells, comprising the following steps: binding a protein shell fragment, via a first region to a matrix; bringing the protein shell fragment bound to the matrix into contact with the molecular substance, in order to bind the molecular substance to a second region of the protein shell fragment; separating the protein shell fragment with the bonded molecular substance, or the part thereof which contains the bonded molecular substance, from the matrix and assembling the separated protein shell fragments, or the part thereof which contains the bonded molecular substance, with other protein shell fragments to form a protein shell, whereby the separation and assembly can be carried out in any order.

Abstract: The invention relates to transport systems for molecular substances, comprising a mosaic of recombinant partial units (individual components). The invention further relates to production of the molecular transport system and use thereof.

Abstract: The invention relates to a method for the transfer of molecular substances, for example proteins or nucleic acids in cells, in the case of using DNA combined with a possible gene expression. A prokaryotic nucleic acid-binding protein is used for the transfer, which is preferably obtained from a thermostable organism. Where the substance to be transferred is a nucleic acid, the protein forms a reversible complex with the nucleic acid. The prokaryotic protein condenses and compacts the nucleic acids. Said nucleic acids can be taken up in the target cells after suitable incubation.

Abstract: The invention provides a process for forming a compound having the formula (I): from chemical entities native [A], native [B] and native [C], where native [A] has a thioester group, native [B] had a 1-amino-2-thiol group with an unoxidised sulfhydryl side chain, and native [C] had a thiol reactive function (TRF) group, wherein chemical entities [A], [B] and [C] are covalently linked by linker group L, comprising the steps of: (i) admixing native [A] and native [B] in a reaction solution; (ii) condensing the unoxidised sulfydryl side chain of native [B] with the thioester group of native [A] for producing a first intermediate compound wherein [A] and [B] are linked with a ?-aminothioester bond; (iii) rearranging the ?-aminothioester bond for producing a second intermediate compound wherein [A] and [B] are linked with an amide bond having attached thereto a free thiol group; (iv) admixing native [C] with the second intermediate compound in a reaction solution; and (v) reacting the thiol reactive function (TRF)